Researchers have found that a decrease in scar-generating cell death called ferroptosis may be a mechanism that drives IPF.

GRI Bio‘s experimental oral therapy GRI-0621 (tazarotene) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF) ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google I recently received my first Rituxan (rituximab) infusion. Most ...

My husband, Donnie, suffered from gastroesophageal reflux disease (GERD) for several years before the onset of his lung issues, and we were surprised to learn of the connection between GERD and ...

A funny thing happened the other day on the way to the Pulmonary Fibrosis News Forums. In the blink of an eye, everything changed, and off I went to the emergency room at Inova Fairfax Hospital in ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

A new startup company called Isterian Biotech has launched with the goal of developing new therapies for fibrotic diseases. Isterian is working to develop a first-in-class group of small molecules ...

Treatment with Ofev (nintedanib) can significantly extend the survival of patients with idiopathic pulmonary fibrosis (IPF), an analysis of pooled data from six clinical trials shows. The analyis, ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) ...

There is currently no cure for pulmonary fibrosis (PF). However, medication and other treatment options can help improve patients’ quality of life, ease symptoms, and slow the disease’s progression.

Enrollment has been completed for a Phase 2b trial that’s testing LYT-100 (deupirfenidone), PureTech Health’s experimental therapy for idiopathic pulmonary fibrosis (IPF). The trial, called ELEVATE ...